Xiamen: lead the social capital to biological medicine enterprise 
 
 
Author: source: xiamen daily 
 
 
Publisher: Zhang Jian shafts 
 
 

Date: 2015-06-26 

    Policy window
 
    Encourage innovation research and development
 
    Of biological drugs, 1-6 type of traditional Chinese medicine (TCM), 1-4 kind of chemicals and three types of medical equipment, research and development, clinical, production of various stages give 500000 yuan, 1 million yuan, 2 million yuan and 5 million yuan of financial appropriation, up to a single project is 20 million yuan RMB
 
    Encourage technology upgrading
 
    The enterprise implementation of pharmaceutical production quality control standard for the transformation, the transformation of scientific and technological achievements, testing and other project priority key technological transformation projects listed in the city, the funding of up to 5 million yuan
 
    Encourage enterprises to international certification
 
    For enterprises to apply for the international market access certification, for biological products international multicenter clinical research or application registered abroad, the highest subsidies of 6 million yuan
 
    Biotechnology and new medicine as xiamen one of the key building (group) billions of industry chain, in recent years, various types of supporting policies and financial capital to its tilt. "This year, zhuhai launched a major move again." Yesterday morning, the city finance bureau inspector Lin Jianzao at xiamen municipal people's government of the nets, xiamen, biological medicine industry development policy: the scale of our city has been set up early for 10 billion dollar industry guide fund, use of fiscal funds "leverage" effect, is expected to move to 40 billion yuan to 40 billion yuan of social capital to enter, including biotechnology and new medicine, strategic emerging industries and high-tech fields, for the cultivation and development of the industry to provide an endless supply of capital supply. 

    Lin Jianzao said, at present the financial sector is to formulate the detailed rules for the implementation of measures, refining the terms of the subsidies subsidies, clear the various subsidies subsidies application process, at the same time, further reduce the decentralization, optimize the approval process, simplify procedures, shortening the time of policy to cash, improve the efficiency of funds allocated. Want to policy utility maximization, make as many biological pharmaceutical companies enjoy the dividend policy.
 
    Financial investing heavily in recent years, city, district two levels, the building covers an area of about 10 square kilometers of xiamen port of biological medicine, agglomeration development of nearly 190 of biotechnology and new medicine enterprises; Municipal finance also invest 270 million yuan, the construction of the sides of the Taiwan straits molecular pathology technical center, Marine biotechnology industry pilot base 26 biotechnology and new medicine, such as public service platform. However, for the enterprise to more worth looking forward to, is the industry guide billions of scale brought about by the social capital accumulation effect.
 
    "Early in February this year, the city set up for ten billion yuan of industrial scale after guiding fund, effect is preliminary already revealed." Lin Jianzao disclosed that recently there are many famous equity investment institutions of biotechnology and new medicine industry showed great interest in zhuhai. At present, xiamen raise collect rich investment management co., LTD., Thailand's biological sciences (China) co., LTD., have proposed equity investment institutions, such as cooperation with industry guide fund, set up two biological medicine industry in our city child fund, can raise 700 million yuan of funds into the field of biotechnology and new medicine, to expand the biotechnology and new medicine enterprise financing channels at the same time, will also with the introduction of excellent management team to provide enterprises with development planning, technology promotion, capital operation, management, optimization, resource grafting and other value-added services, to promote the city enterprises bigger and stronger.
 
    "In the industry leading funds and two industry leads, the future will be more and more social capital to the areas of biotechnology and new medicine agglomeration." He said that in the future, the city will also through new or improve the nursery space, innovation, small micro enterprise incubator, accelerator, experimental base, industrial park, industrial base, and implementation of old factory building, remolding old warehouse, create and expand for biotechnology and new medicine industry development space. In a variety of policy positive backdrop, predicts 2018, the zhuhai biotechnology and new medicine industry will develop 100 hundreds of millions of yuan enterprises, achieve 100 billion yuan of industrial value.